
Ology Bioservices (AKA: Nanosphere Inc~Nanocoat Technologies Inc~Nanotherapeutics Inc) Profile last edited on: 5/28/2021
CAGE: 3GQS9
UEI:
Business Identifier: Pre-clinical and clinical development, formulation, clinical trial management, and cGMP manufacturing Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
13859 Progress Boulevard Suite 300
Alachua, FL 32615
Alachua, FL 32615
(386) 462-9663 |
info@nanotherapeutics.com |
www.nanotherapeutics.com |
Location: Single
Congr. District: 03
County: Alachua
Congr. District: 03
County: Alachua
Public Profile
Ology Bio is a biologics CDMO specializing in single use processes up to BSL-3. Though having fairly extensive previous SBIR involvement, the last SBIR dollars we awarded in 2015. In April 2021 it was announced that the curently named firm had been acquired by a much smaller firm out of La Jolla CAm(dba Resilience) providing end-to-end biopharmaceutical manufacturing and development solutions and having already raised some $800M. _____________ Previous history: In April 2017, Nanotherapeutics - a specialty biopharmaceutical company with full product development, cGMP manufacturing capabilities, and a proprietary pipeline - was acquired by Serum Institute of India Pvt. Ltd. Formerly dba Nanosphere, Inc. Nanotherapeutics, Inc. is was renamed as Ology Bioservices in Oct 2017. The firm functions as a biopharmaceutical company specializing in the pre-clinical and clinical development, formulation, clinical trial management, and cGMP manufacturing of a pipeline of pharmaceutical products and medical devices. With major focus on developing a diversified proprietary pipeline of products having both biodefense and medical applications. products under development include biodefense, CNS, wound healing, addiction and pain, oncology, anti-infectives and orthopedics. At various point after 2009 and before its own acqusiiton, the firm was active in acquiring the assets of other small firms in trouble and/or closing up shop.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
250-500Revenue Range
20M-50MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
50-74Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2015 | 2 | NIH | $3,571,476 | |
Project Title: Gelvac Stable, Dry-Powder Nasal Recombinant Vlp-Based Bivalent Norovirus Vaccine | ||||
2011 | 2 | NIH | $595,945 | |
Project Title: Development of a Synthetic Typhoid Fever Vaccine as a Substitution of Vi Vaccine | ||||
2008 | 2 | NIH | $991,004 | |
Project Title: Oral Buprenorphine Nanoparticle Formulation | ||||
2006 | 2 | Navy | $1,040,620 | |
Project Title: Technologies to Defeat Improvised Explosive Devices (IED's) | ||||
2005 | 1 | Army | $69,938 | |
Project Title: Antimicrobial Bone Graft Substitute |
Key People / Management
Peter H Khoury -- President and CEO
James D Talton -- Co-founder, President and CEO
John Abernethy -- Medical Director
Gary A Ascani -- Vice President, Business Development
Ronald Cobb -- Chief Scientific Officer
Barbel Eppler -- Senior VP of Preclinical Development and QA
Weaver H Gaines -- Chairman of the Board and General Counsel
Guenther Hochhaus
James F Kirk -- Vice President, Research and Development
Dennis Tomisaka -- Senior Vice President, Operations
James D Talton -- Co-founder, President and CEO
John Abernethy -- Medical Director
Gary A Ascani -- Vice President, Business Development
Ronald Cobb -- Chief Scientific Officer
Barbel Eppler -- Senior VP of Preclinical Development and QA
Weaver H Gaines -- Chairman of the Board and General Counsel
Guenther Hochhaus
James F Kirk -- Vice President, Research and Development
Dennis Tomisaka -- Senior Vice President, Operations